Genetically Engineered Animals, Drugs, and Neoliberalism: The Need for a New Biotechnology Regulatory Policy Framework

被引:0
|
作者
Zahra Meghani
机构
[1] University of Rhode Island,Philosophy Department
关键词
GE (genetically engineered) animals; Drugs; Food and Drug Administration (FDA); Coordinated Framework for Regulating Biotechnology (CFRB); Neoliberalism; Sociotechnical imaginary;
D O I
暂无
中图分类号
学科分类号
摘要
Genetically engineered (GE) animals that are meant for release in the wild could significantly impact ecosystems given the interwoven or entangled existence of species. Therefore, among other things, it is all too important that regulatory agencies conduct entity appropriate, rigorous risk assessments that can be used for informed decision-making at the local, national and global levels about the release of those animals in the wild. In the United States (US), certain GE animals that are intended for release in the wild may be regulated as new animal drugs by the Food and Drug Administration. This paper argues that the decision to treat them as new animal drugs is attributable to the influence of neoliberalism on the US biotechnology regulatory policy framework. The case is made that there should be public democratic deliberations and decision-making about the values and concerns that should guide the nation’s biotechnology regulatory policy paradigm, including the risk assessment process for GE animals meant for release in the wild.
引用
收藏
页码:715 / 743
页数:28
相关论文
共 35 条
  • [1] Genetically Engineered Animals, Drugs, and Neoliberalism: The Need for a New Biotechnology Regulatory Policy Framework
    Meghani, Zahra
    [J]. JOURNAL OF AGRICULTURAL & ENVIRONMENTAL ETHICS, 2017, 30 (06): : 715 - 743
  • [2] A REGULATORY POLICY FRAMEWORK FOR BIOTECHNOLOGY
    SCOTT, CN
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF TOXICOLOGY, 1985, 4 (06): : 373 - 373
  • [3] A new paradigm for regulating genetically engineered animals that are used as food
    Murray, J. D.
    Maga, E. A.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2016, 113 (13) : 3410 - 3413
  • [4] Biotechnology executive order opens door for regulatory reform and social acceptance of genetically engineered microbes in agriculture
    Ahmad, Jabeen
    Grunden, Amy
    Kuzma, Jennifer
    [J]. GM CROPS & FOOD-BIOTECHNOLOGY IN AGRICULTURE AND THE FOOD CHAIN, 2024, 15 (01): : 248 - 261
  • [5] Regulating animals with gene drive systems: lessons from the regulatory assessment of a genetically engineered mosquito
    Meghani, Zahra
    Kuzma, Jennifer
    [J]. JOURNAL OF RESPONSIBLE INNOVATION, 2018, 5 : S203 - S222
  • [6] INVESTIGATIONAL NEW DRUGS - FDA REGULATORY POLICY
    GINZBURG, HM
    [J]. PEDIATRIC AIDS AND HIV INFECTION-FETUS TO ADOLESCENT, 1992, 3 (04): : 202 - 212
  • [7] Manufacture of genetically engineered drugs - A new class of active substances challenging analysis and evaluation
    Dingermann, T
    [J]. PHARMAZEUTISCHE INDUSTRIE, 1997, 59 (04): : 348 - 351
  • [8] PET drugs and cGMP: Challenges within the new regulatory framework
    Gameiro, Cristiana
    Amaral, Horacio
    Amaral, Andres
    Schmitz, Alexander
    Poria, Rahul
    Freifelder, Richard
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2012, 53
  • [9] Bringing science to life in Australia: the need for a new approach in human health biotechnology policy
    Marceau, Jane
    [J]. JOURNAL OF TECHNOLOGY TRANSFER, 2007, 32 (04): : 303 - 327
  • [10] A comprehensive regulatory framework to address the unmet need for new antibacterial treatments
    Rex, John H.
    Eisenstein, Barry I.
    Alder, Jeff
    Goldberger, Mark
    Meyer, Robert
    Dane, Aaron
    Friedland, Ian
    Knirsch, Charles
    Sanhai, Wendy R.
    Tomayko, John
    Lancaster, Cindy
    Jackson, Jennifer
    [J]. LANCET INFECTIOUS DISEASES, 2013, 13 (03): : 269 - 275